NASDAQ:MIRM

Mirum Pharmaceuticals Stock Forecast, Price & News

$17.78
+0.35 (+2.01 %)
(As of 06/14/2021 11:36 AM ET)
Add
Compare
Today's Range
$17.44
$17.79
50-Day Range
$15.84
$20.32
52-Week Range
$15.22
$27.43
Volume319 shs
Average Volume118,972 shs
Market Capitalization$541.45 million
P/E RatioN/A
Dividend YieldN/A
Beta2.32
30 days | 90 days | 365 days | Advanced Chart
Receive MIRM News and Ratings via Email

Sign-up to receive the latest news and ratings for Mirum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Mirum Pharmaceuticals logo

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company's lead product candidate is Maralixibat, an investigational oral drug that is in Phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It is also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. The company was incorporated in 2018 and is headquartered in Foster City, California.

Headlines

Mirum Pharmaceuticals (NASDAQ:MIRM) Trading Down 5.4%
Mirum Pharmaceuticals (NASDAQ:MIRM) Trading Down 5.4%
May 24, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.86 out of 5 stars

Medical Sector

152nd out of 2,099 stocks

Pharmaceutical Preparations Industry

69th out of 831 stocks

Analyst Opinion: 3.6Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Mirum Pharmaceuticals (NASDAQ:MIRM) Frequently Asked Questions

Is Mirum Pharmaceuticals a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mirum Pharmaceuticals in the last twelve months. There are currently 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Mirum Pharmaceuticals stock.
View analyst ratings for Mirum Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Mirum Pharmaceuticals?

Wall Street analysts have given Mirum Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Mirum Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Mirum Pharmaceuticals' next earnings date?

Mirum Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Mirum Pharmaceuticals
.

How were Mirum Pharmaceuticals' earnings last quarter?

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) announced its quarterly earnings results on Thursday, May, 6th. The company reported ($1.68) earnings per share for the quarter, missing the consensus estimate of ($0.67) by $1.01.
View Mirum Pharmaceuticals' earnings history
.

How has Mirum Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

Mirum Pharmaceuticals' stock was trading at $11.73 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MIRM shares have increased by 50.0% and is now trading at $17.60.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for MIRM?

7 analysts have issued 12 month price objectives for Mirum Pharmaceuticals' shares. Their forecasts range from $30.00 to $52.00. On average, they expect Mirum Pharmaceuticals' share price to reach $40.17 in the next year. This suggests a possible upside of 128.2% from the stock's current price.
View analysts' price targets for Mirum Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Mirum Pharmaceuticals' key executives?

Mirum Pharmaceuticals' management team includes the following people:
  • Mr. Christopher Peetz, Pres, CEO & Director (Age 42, Pay $785.22k)
  • Dr. Ian Clements, Chief Financial Officer (Age 52, Pay $541.15k)
  • Mr. Peter Radovich M.B.A., Ph.D., Chief Operating Officer (Age 43, Pay $524.85k)
  • Dr. Pamela Vig Ph.D., Chief Scientific Officer (Age 50)
  • Mr. Paul K. Ross, Chief Compliance Officer
  • Ms. Lara Longpre MSC, MBA, Chief Devel. Officer (Age 51)
  • Dr. Edwin Jonathan Tucker M.D., Chief Medical Officer (Age 49)

Who are some of Mirum Pharmaceuticals' key competitors?

What other stocks do shareholders of Mirum Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mirum Pharmaceuticals investors own include Pfizer (PFE), Fulcrum Therapeutics (FULC), OPKO Health (OPK), Vaxart (VXRT), Advanced Micro Devices (AMD), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), Trevena (TRVN), VBI Vaccines (VBIV) and Dynavax Technologies (DVAX).

When did Mirum Pharmaceuticals IPO?

(MIRM) raised $75 million in an initial public offering (IPO) on Thursday, July 18th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Evercore ISI and Guggenheim Securities served as the underwriters for the IPO and Raymond James and Roth Capital Partners were co-managers.

What is Mirum Pharmaceuticals' stock symbol?

Mirum Pharmaceuticals trades on the NASDAQ under the ticker symbol "MIRM."

Who are Mirum Pharmaceuticals' major shareholders?

Mirum Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Rock Springs Capital Management LP (4.93%), BlackRock Inc. (2.50%), Geode Capital Management LLC (0.57%), Northern Trust Corp (0.32%), Millennium Management LLC (0.27%) and Chartwell Investment Partners LLC (0.22%). Company insiders that own Mirum Pharmaceuticals stock include Christopher Peetz, Edwin Jonathan Tucker, Holdings A/S Novo, Ian Clements, James E Flynn, Laurent Fischer, Pamela Vig and Patrick J Heron.
View institutional ownership trends for Mirum Pharmaceuticals
.

Which institutional investors are selling Mirum Pharmaceuticals stock?

MIRM stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Nuveen Asset Management LLC, Chartwell Investment Partners LLC, Cubist Systematic Strategies LLC, Northern Trust Corp, and Bank of New York Mellon Corp.
View insider buying and selling activity for Mirum Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Mirum Pharmaceuticals stock?

MIRM stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Geode Capital Management LLC, Panagora Asset Management Inc., Los Angeles Capital Management LLC, JPMorgan Chase & Co., GSA Capital Partners LLP, Pinnacle Advisory Group Inc., and Alps Advisors Inc.. Company insiders that have bought Mirum Pharmaceuticals stock in the last two years include Christopher Peetz, Edwin Jonathan Tucker, Holdings A/S Novo, Ian Clements, James E Flynn, Laurent Fischer, Pamela Vig, and Patrick J Heron.
View insider buying and selling activity for Mirum Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Mirum Pharmaceuticals?

Shares of MIRM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mirum Pharmaceuticals' stock price today?

One share of MIRM stock can currently be purchased for approximately $17.60.

How much money does Mirum Pharmaceuticals make?

Mirum Pharmaceuticals has a market capitalization of $535.97 million. The company earns $-103,270,000.00 in net income (profit) each year or ($4.09) on an earnings per share basis.

How many employees does Mirum Pharmaceuticals have?

Mirum Pharmaceuticals employs 85 workers across the globe.

What is Mirum Pharmaceuticals' official website?

The official website for Mirum Pharmaceuticals is mirumpharma.com.

Where are Mirum Pharmaceuticals' headquarters?

Mirum Pharmaceuticals is headquartered at 950 TOWER LANE SUITE 1050, FOSTER CITY CA, 94404.

How can I contact Mirum Pharmaceuticals?

Mirum Pharmaceuticals' mailing address is 950 TOWER LANE SUITE 1050, FOSTER CITY CA, 94404. The company can be reached via phone at 650-667-4085 or via email at [email protected]


This page was last updated on 6/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.